Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.…
Allogeneic Cell Therapy - Global Strategic Business Report 2026: Capitalize on 27.7% CAGR to Capture $2.4B by 2032 with Allogene, Gilead Sciences, Atara and Nkarta
Nkarta (NASDAQ: NKTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 103 employees.
The shares were at 1.135 USD on 20 November 2026, down 42.1% over 52 weeks. Its 52-week range is 1.105 USD to 3.715 USD: the price is 69.4% below the high and 2.7% above the low.
Its market capitalisation is 81.29M USD.
Nkarta reports return on equity of -33.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 84.57M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.